US Food and Drug Administration approvals continued at breakneck pace with 12 new molecular and biological entities. These included Roche's long-anticipated antibody-drug conjugate Kadcyla and Janssen's first-in-class sodium glucose type 2 transporter Invokana. The quarter was not without disappointment, however; in particular, Affymax recalled its recently approved erythropoietin mimetic Omontys.

Historic US regulatory approvals by drug class

Notable regulatory setbacks (Q1 2013)

Notable upcoming regulatory decisions (Q3 2013)

Notable clinical trial results (Q1 2013)

Notable regulatory approvals (Q1 2013)